The research appears as the "Paper of the Week" in the May 27 issue of the Journal of Biological Chemistry, an American Society for Biochemistry and Molecular Biology journal.
Multidrug resistance is very common in most types of cancers, making it one of the leading problems in cancer therapy. It is often caused by an increase in the cell's production of proteins that transport drugs out of the cell, preventing the drugs from combating cancer.
Previously, Dr. Bryan P. Toole and his coworkers, Drs. Suniti Misra and Shibnath Ghatak, of the Medical University of South Carolina noticed that small pieces, or oligomers, of a polysaccharide called hyaluronan were able to sensitize drug-resistant breast cancer cells to several different chemotherapeutic drugs. He believed that the polysaccharide oligomers were binding to a receptor for hyaluronan (called CD44) and preventing it from initiating a signaling cascade that would result in drug resistance.
"It is very surprising that hyaluronan is involved in drug resistance," admits Dr. Toole. "Most scientists think of hyaluronan as a structural and inert molecule. In adult tissues it plays two roles. First, it assists in tissue hydration and in biophysical properties such as resilience. Second, it forms a template to which matrix proteins attach and form important extracellular structural complexes."
Hyaluronan also accumulates around the outside of cells during disease processes such as early atherogenesis, persistent inflammation, and cancer. In recent years, however, hyaluronan has also been shown to induce signaling
'"/>
Source:American Society for Biochemistry and Molecular Biology